On Thursday, AstraZeneca (NASDAQ:AZN) raised its full-year adjusted earnings forecast after Q3 profit and revenue topped analysts’ expectations due to sales of its key cancer drugs.

Oncology is AstraZeneca’s biggest disease area. Notably, cancer drugs accounted for close to 36 per cent of the London-listed drugmaker’s total product sales last year.

Sales of Tagrisso and Imfinzi, AstraZeneca’s key cancer medicines, helped the firm’s quarterly revenue beat. Reportedly, sales of its broader oncology portfolio grew 24 per cent. While Tagrisso generated nearly USD 1.4 billion, Imfinzi brought in USD 737 million in the quarter. Reportedly, Label expansions for Tagrisso, Imfinzi, Lynparza and Enhertu have driven prescription growth. The company now expects its full-year adjusted profit per share to grow by a high twenties to low thirties percentage.

The London-listed company’s shares ascended nearly 2 per cent in early trading.